Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 153

1.

Development and validation of a prostate cancer genomic signature that predicts early ADT treatment response following radical prostatectomy.

Karnes RJ, Sharma V, Choeurng V, Al-Deen Ashab H, Erho NG, Alshalalfa M, Trock BJ, Ross AE, Yousefi K, Tsai HK, Zhao SG, Tosoian JJ, Haddad Z, Takhar M, Chang SL, Spratt DE, Abdollah F, Jenkins RB, Klein EA, Nguyen PL, Dicker AP, Den RB, Davicioni E, Feng FY, Lotan TL, Schaeffer EM.

Clin Cancer Res. 2018 May 14. pii: clincanres.2745.2017. doi: 10.1158/1078-0432.CCR-17-2745. [Epub ahead of print]

PMID:
29760221
2.

Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer.

Yang L, Roberts D, Takhar M, Erho N, Bibby BAS, Thiruthaneeswaran N, Bhandari V, Cheng WC, Haider S, McCorry AMB, McArt D, Jain S, Alshalalfa M, Ross A, Schaffer E, Den RB, Jeffrey Karnes R, Klein E, Hoskin PJ, Freedland SJ, Lamb AD, Neal DE, Buffa FM, Bristow RG, Boutros PC, Davicioni E, Choudhury A, West CML.

EBioMedicine. 2018 May;31:182-189. doi: 10.1016/j.ebiom.2018.04.019. Epub 2018 Apr 23.

3.

Improvement in Therapeutic Efficacy and Reduction in Cellular Toxicity: Introduction of a Novel Anti-PSMA-Conjugated Hybrid Antiandrogen Nanoparticle.

Thangavel C, Perepelyuk M, Boopathi E, Liu Y, Polischak S, Deshpande DA, Rafiq K, Dicker AP, Knudsen KE, Shoyele SA, Den RB.

Mol Pharm. 2018 May 7;15(5):1778-1790. doi: 10.1021/acs.molpharmaceut.7b01024. Epub 2018 Apr 4.

PMID:
29616555
4.

Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer.

Mahal BA, Yang DD, Wang NQ, Alshalalfa M, Davicioni E, Choeurng V, Schaeffer EM, Ross AE, Spratt DE, Den RB, Martin NE, Mouw KW, Orio PF 3rd, Choueiri TK, Taplin ME, Trinh QD, Feng FY, Nguyen PL.

Eur Urol. 2018 Feb 22. pii: S0302-2838(18)30098-8. doi: 10.1016/j.eururo.2018.01.043. [Epub ahead of print]

PMID:
29478736
5.

Utilizing 10-Year Results From the American Board of Radiology Clinical Examination to Identify Areas for Programmatic Improvement.

Den RB, Folino M, Dicker AP.

Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):556-557. doi: 10.1016/j.ijrobp.2017.11.032. Epub 2017 Nov 27. No abstract available.

PMID:
29413270
6.

Current perspectives on bone metastases in castrate-resistant prostate cancer.

Logothetis C, Morris MJ, Den R, Coleman RE.

Cancer Metastasis Rev. 2018 Mar;37(1):189-196. doi: 10.1007/s10555-017-9719-4. Review.

7.

Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features.

Hwang WL, Tendulkar RD, Niemierko A, Agrawal S, Stephans KL, Spratt DE, Hearn JW, Koontz BF, Lee WR, Michalski JM, Pisansky TM, Liauw SL, Abramowitz MC, Pollack A, Moghanaki D, Anscher MS, Den RB, Zietman AL, Stephenson AJ, Efstathiou JA.

JAMA Oncol. 2018 May 10;4(5):e175230. doi: 10.1001/jamaoncol.2017.5230. Epub 2018 May 10.

PMID:
29372236
8.

Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer.

Thangavel C, Boopathi E, Liu Y, McNair C, Haber A, Perepelyuk M, Bhardwaj A, Addya S, Ertel A, Shoyele S, Birbe R, Salvino JM, Dicker AP, Knudsen KE, Den RB.

Clin Cancer Res. 2018 Mar 15;24(6):1402-1414. doi: 10.1158/1078-0432.CCR-17-2074. Epub 2018 Jan 8.

PMID:
29311118
9.

Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG.

J Clin Oncol. 2018 Feb 1;36(4):414-424. doi: 10.1200/JCO.2017.74.1173. Epub 2017 Dec 13.

PMID:
29236593
10.

Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy.

Spratt DE, Dai DLY, Den RB, Troncoso P, Yousefi K, Ross AE, Schaeffer EM, Haddad Z, Davicioni E, Mehra R, Morgan TM, Rayford W, Abdollah F, Trabulsi E, Achim M, Tapia ELN, Guerrero M, Karnes RJ, Dicker AP, Hurwitz MA, Nguyen PL, Feng FFY, Freedland SJ, Davis JW.

Eur Urol. 2018 Jul;74(1):107-114. doi: 10.1016/j.eururo.2017.11.024. Epub 2017 Dec 10.

PMID:
29233664
11.

Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.

Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choeurng V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL.

J Clin Oncol. 2018 Feb 20;36(6):581-590. doi: 10.1200/JCO.2017.74.2940. Epub 2017 Nov 29.

PMID:
29185869
12.

Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer.

Ramey SJ, Agrawal S, Abramowitz MC, Moghanaki D, Pisansky TM, Efstathiou JA, Michalski JM, Spratt DE, Hearn JWD, Koontz BF, Liauw SL, Pollack A, Anscher MS, Den RB, Stephans KL, Zietman AL, Lee WR, Stephenson AJ, Tendulkar RD.

Eur Urol. 2018 Jul;74(1):99-106. doi: 10.1016/j.eururo.2017.10.009. Epub 2017 Nov 9.

PMID:
29128208
13.

TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup.

Labbé DP, Sweeney CJ, Brown M, Galbo P, Rosario S, Wadosky KM, Ku SY, Sjöström M, Alshalalfa M, Erho N, Davicioni E, Karnes RJ, Schaeffer EM, Jenkins RB, Den RB, Ross AE, Bowden M, Huang Y, Gray KP, Feng FY, Spratt DE, Goodrich DW, Eng KH, Ellis L.

Clin Cancer Res. 2017 Nov 15;23(22):7072-7083. doi: 10.1158/1078-0432.CCR-17-0413. Epub 2017 Sep 12.

PMID:
28899973
14.

Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients.

Alshalalfa M, Verhaegh GW, Gibb EA, Santiago-Jiménez M, Erho N, Jordan J, Yousefi K, Lam LLC, Kolisnik T, Chelissery J, Seiler R, Ross AE, Karnes RJ, Schaeffer EM, Lotan TT, Den RB, Freedland SJ, Davicioni E, Klein EA, Schalken JA.

Oncotarget. 2017 Feb 7;8(31):50804-50813. doi: 10.18632/oncotarget.15133. eCollection 2017 Aug 1.

15.

The Role of Genomic Techniques in Predicting Response to Radiation Therapy.

Williams NL, Dan T, Zaorsky NG, Garg S, Den RB.

Oncology (Williston Park). 2017 Jul 15;31(7):562-70. Review.

16.

Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy.

Yang DD, Muralidhar V, Mahal BA, Nezolosky MD, Labe SA, Vastola ME, Boldbaatar N, King MT, Martin NE, Orio PF 3rd, Choueiri TK, Trinh QD, Den RB, Spratt DE, Hoffman KE, Feng FY, Nguyen PL.

Urol Oncol. 2017 Sep;35(9):542.e25-542.e32. doi: 10.1016/j.urolonc.2017.04.018. Epub 2017 May 19.

PMID:
28533151
17.

Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy.

Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M, Speers C, Cooperberg MR, Kim W, Ryan CJ, Den RB, Freedland SJ, Posadas E, Sandler H, Klein EA, Black P, Seiler R, Tomlins SA, Chinnaiyan AM, Jenkins RB, Davicioni E, Ross AE, Schaeffer EM, Nguyen PL, Carroll PR, Karnes RJ, Spratt DE, Feng FY.

JAMA Oncol. 2017 Dec 1;3(12):1663-1672. doi: 10.1001/jamaoncol.2017.0751.

18.

Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease.

Spratt DE, Yousefi K, Deheshi S, Ross AE, Den RB, Schaeffer EM, Trock BJ, Zhang J, Glass AG, Dicker AP, Abdollah F, Zhao SG, Lam LLC, du Plessis M, Choeurng V, Haddad Z, Buerki C, Davicioni E, Weinmann S, Freedland SJ, Klein EA, Karnes RJ, Feng FY.

J Clin Oncol. 2017 Jun 20;35(18):1991-1998. doi: 10.1200/JCO.2016.70.2811. Epub 2017 Mar 30. Review.

PMID:
28358655
19.

Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model.

Dalela D, Santiago-Jiménez M, Yousefi K, Karnes RJ, Ross AE, Den RB, Freedland SJ, Schaeffer EM, Dicker AP, Menon M, Briganti A, Davicioni E, Abdollah F.

J Clin Oncol. 2017 Jun 20;35(18):1982-1990. doi: 10.1200/JCO.2016.69.9918. Epub 2017 Mar 28.

PMID:
28350520
20.

Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.

Mo F, Lin D, Takhar M, Ramnarine VR, Dong X, Bell RH, Volik SV, Wang K, Xue H, Wang Y, Haegert A, Anderson S, Brahmbhatt S, Erho N, Wang X, Gout PW, Morris J, Karnes RJ, Den RB, Klein EA, Schaeffer EM, Ross A, Ren S, Sahinalp SC, Li Y, Xu X, Wang J, Wang J, Gleave ME, Davicioni E, Sun Y, Wang Y, Collins CC.

Eur Urol. 2018 Apr;73(4):524-532. doi: 10.1016/j.eururo.2017.02.038. Epub 2017 Mar 19.

PMID:
28330676

Supplemental Content

Support Center